Omeprazol Gp (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Gp, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is employed in the treatment of acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Omeprazol Gp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Omeprazole is a proton pump inhibitor that acts on the gastric parietal cell to lower acid production, addressing several acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining higher gastric pH. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence by suppressing acid secretion. - Zollinger‑Ellison syndrome: controls excessive gastric acid output associated with gastrin‑producing tumors. - NSAID‑induced ulcer prophylaxis: reduces risk of ulcer formation in patients regularly using non‑steroidal anti‑inflammatory drugs.

Omeprazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk with prolonged use. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Hypomagnesemia: low magnesium levels with long‑term therapy. - Bone fracture risk: increased incidence with extended treatment. - Hepatic enzyme elevation: potential liver function changes. - Interstitial nephritis: rare kidney inflammation.

When prescribing Omeprazole, clinicians should consider several safety aspects. - Assess renal function: adjust use in severe renal impairment. - Avoid in known hypersensitivity to omeprazole or other PPIs. - Use with caution in patients with liver disease: monitor hepatic enzymes. - Consider risk of osteoporosis: long‑term use may increase fracture risk. - Monitor magnesium levels: prolonged therapy can cause hypomagnesemia. - Store at room temperature: keep in the original pack, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased antiviral absorption. - Methotrexate (high dose): increased toxicity.

Moderate Interactions (Monitor Closely): - Digoxin: possible increase in serum concentration. - Iron supplements: reduced iron absorption.